1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1620
  5. Art Unit 1623
  6. Examiner Mcmillian

Examiner Mcmillian Kara R

1623-MCMILLIAN-KARA-R

Employment Information

Art Unit:1623 — Drug, bio-affecting and body treating compositions
Group:1620 — Biomedicinal Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
424 — Drug, bio-affecting and body treating compositions
604 — Surgery
435 — Chemistry: molecular biology and microbiology
540 — Organic compounds -- part of the class 532-570 series
436 — Chemistry: analytical and immunological testing
206 — Special receptacle or package
702 — Data processing: measuring, calibrating, or testing
Phone:(571) 270-5236
Email:kara.mcmillian@uspto.gov
Location:VA 22314
Title:Pat Examnr Phrmcolgy
Service:18 years
Grade:GS-14

Grant Rate and Difficulty Ranking

92
3-Year Grant rate: 26% over 311 cases
Difficulty: Extremely Hard
Difficulty Percentile: 92nd

With Examiner Mcmillian, you have a 26% chance of getting an issued patent by 3 years after the first office action. Examiner Mcmillian is an extremely hard examiner and in the 92nd percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Mcmillian, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1623

Examiner Mcmillian's grant rate is lower than that of Art Unit 1623 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Mcmillian 2.7
Art Unit 1623 1.5

Interview Benefit

Grant Rate without Interview

Examiner Mcmillian has granted 57 of 233 cases without any applicant-requested interviews for a grant rate of 24%.

Grant Rate with Interview

Examiner Mcmillian has granted 25 of 78 cases with at least one applicant-requested interview for a grant rate of 32%.

Interview Benefit

With Examiner Mcmillian, conducting an interview increases your chance of getting a patent granted by 33%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17788487 Method Of Treating Virus Infection Using A Tlr7 Agonist Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
17755084 Schizophrenic Disorder Treatment Using Combination Therapy Patented View
17325068 Inhibitors Of Alpha-Amino-Beta-Carboxymuconic Acid Semialdehyde Decarboxylase Abandoned View
17052192 Novel Heterocycle Derivative Patented View
17426805 Novel Devices Abandoned View
17774051 Inhibitor Of Binding Between Podocin And Keratin 8 For Use In The Treatment Of Nephrotic Syndrome Abandoned View
17579271 Next Generation Remdesivir Antivirals Patented View
17602910 Stabilization Of Suspension Concentrates By Highly Sulfonated Lignosulfonate Abandoned View
17605456 Dihydropyrimidine Compound And Application Thereof As Drug Abandoned View
18181228 Preventive Treatment Of Migraine Abandoned View
18907258 S-Beta-Hydroxybutyric Acid Compositions And Methods For Delivery Of Ketone Bodies Patented View
18063486 Synergistic Effects, Augmenting Antimicrobal Effects Of Lipids Abandoned View
17849803 Liquid Compositions Comprising Terpenes And Cannabinoids Abandoned View
18948449 Use Of Ergothioneine To Suppress Deleterious Effects Of Senescence Abandoned View
17309764 Heterocyclyl Pyridazine As Fungicidal Compounds Patented View
17766081 Pharmacological Composition For Treating Proctological Diseases (Variants) Abandoned View
17602028 Benzimidazole Derivatives And Their Uses Patented View
17763597 Pharmaceutical Composition For Preventing Or Treating Sarcopenia, Containing Unnatural Amino Acid Abandoned View
18141170 Treprostinil Prodrugs Abandoned View
17258724 Use Of Compound In Drug For Preventing, Treating, Or Alleviating Pain Abandoned View
18796446 Methods For Preventing Ectopic Brain Mineralization In Alzheimer's Disease And Dementias Abandoned View
17624629 Imidazothiazole Compounds And Methods For Treating Plant Nematode Infections Abandoned View
17331599 Aryl Compounds For The Treatment And Prophylaxis Of Bacterial Infection Abandoned View
18908587 Compositions Of Grapiprant And Methods For Using The Same Patented View
17608950 Ezh2 Inhibitor And Use Thereof Patented View
17780936 Pharmaceutical Composition, For Preventing Or Treating Fibrosis, Comprising Pheophorbide Compound As Active Ingredient Abandoned View
18594233 Method Of Treating Cancer Using Selective Estrogen Receptor Modulators Abandoned View
17768130 Combination Therapy For Treating A Hematological Malignancy Abandoned View
17600172 Compositions And Methods To Treat Non-Alcoholic Fatty Liver Diseases (Nafld) Abandoned View
17779730 Prophylactic Or Therapeutic Agent For Non-Alcoholic Steatohepatitis In Humans Abandoned View
18305589 Pharmaceutical Compositions Comprising A Dextromethorphan Compound And Quinidine For The Treatment Of Agitation In Dementia Abandoned View
17768113 Improved Topical Composition Of Colchicine Abandoned View
17603386 Prodrug Of Caspase Inhibitor Abandoned View
17762666 Treatment Comprising The Use Of Fxr Agonists Abandoned View
17397984 Aryl Sulfide Comprising Benzylamine, Synthesis Method And Application Thereof Patented View
18406539 Topical Formulations Of Chloroprocaine And Methods Of Using Same Abandoned View
18364796 Therapy Of Post-Operative Emesis With Amisulpride Abandoned View
17441222 Pharmaceutical Composition For Treating Macular Degeneration Including Imidazoline Derivative Compound As Active Ingredient Abandoned View
17713384 Osteogenic Agents And Uses Thereof Patented View
18223177 Deuterated Derivatives Of Psilocybin And Uses Thereof Abandoned View
16419927 Method For Activating Ampk And The Use Of Adenine Abandoned View
17600194 Compositions And Methods To Treat Non-Alcoholic Fatty Liver Diseases (Nafld) Abandoned View
18888371 Solid Psilocin Salts Patented View
17331366 Methods Of Treating Thrombosis Patented View
18349221 Acetyl-Leucine Or A Pharmaceutically Acceptable Salt Thereof For Improved Mobility And Cognitive Function Patented View
17289816 Targeting The Transcription Factor Nf-Kb With Harmine Abandoned View
18376339 Injectable Ibuprofen Formulation Abandoned View
18515734 Treating Pain Associated With Chemotherapy-Induced Peripheral Neuropathy Patented View
17381857 Compounds, Targets And Pathways For Macrophage Modulation Abandoned View
16419892 Method For Activating Ampk And The Use Of Adenine Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.